# Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

> **NCT05630872** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 30 (actual)

## Conditions studied

- HIV-associated Tuberculosis

## Interventions

- **DRUG:** Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC
- **DRUG:** DTG 50 mg orally QD plus TDF/3TC
- **DRUG:** 2HPZM
- **DRUG:** 2HPM

## Key facts

- **NCT ID:** NCT05630872
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-13
- **Primary completion:** 2025-05-07
- **Final completion:** 2025-11-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-08

## Collaborators

- ViiV Healthcare
- Mylan Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630872, "Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05630872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*